Fenilcetonúria (PKU) é um erro inato do metabolismo causado pela deficiência da atividade da enzima fenilalanina hidroxilase, levando ao acúmulo de fenilalanina e seus metabólitos no sangue e tecidos. A hiperfenilalaninemia (HPA) causa danos importantes no cérebro, provavelmente causados por aumento de estresse oxidativo e diminuição da disponibilidade dos outros aminoácidos grandes neutros (LNAA), entre outros mecanismos. Pacientes diagnosticados precocemente também estão sujeitos a estes desequilíbrios. O objetivo deste trabalho foi verificar em ratos: a) o efeito agudo do modelo de HPA na concentração de aminoácidos em plasma e cérebro total, b) o efeito do exercício regular em parâmetros de estresse oxidativo em cérebro total, conteúdo de catecolaminas em supra-renal e aspectos comportamentais na HPA crônica. Para o modelo agudo, os ratos foram divididos nos grupos HPA e Salina (SAL) (n=3). A HPA foi induzida através da administração subcutânea de alfa-metil-fenilalanina e fenilalanina, enquanto o grupo SAL recebeu salina. Os animais foram mortos 1 h após a injeção, no segundo dia de tratamento. Para o modelo crônico, os animais foram distribuídos no grupo Sedentário (Sed) ou Exercício (Exe), e subdivididos em SAL e HPA. Grupos HPA (n=16- 20) foram submetidos ao modelo durante 17 dias, enquanto os grupos SAL (n=16-20) receberam salina. Os grupos Exe realizaram duas semanas de exercício aeróbico com duração diária de 20 min. No 17º dia, 1 h após a injeção, os animais realizaram a primeira exposição ao teste de campo aberto e, 24 h depois, realizaram a segunda sessão. Após, os animais foram mortos e o cérebro total foi homogeneizado para determinação da lipoperoxidação, através do conteúdo de substâncias reativas ao ácido tiobarbitúrico (TBA-RS), e atividade das enzimas antioxidantes superóxido dismutase (SOD), catalase (CAT) e glutationa peroxidase (GPx). As glândulas supra-renais foram coletadas para análise de conteúdo de catecolaminas. O efeito agudo de HPA causou aumento de fenilalanina e diminuição de tirosina em plasma e cérebro, bem como diminuiu os níveis dos outros LNAA apenas no cérebro. Cronicamente, a HPA causou aumento de TBA-RS e SOD, e redução de CAT, GPx e conteúdo de catecolaminas. O exercício foi capaz de reverter todas as alterações encontradas no grupo HPA, exceto para a SOD. Quanto aos parâmetros comportamentais, a HPA causou diminuição na memória de habituação e o exercício regular preveniu esta alteração. Nenhuma alteração foi encontrada no grupo ExeSAL. Os ratos hiperfenilalaninêmicos foram mais responsivos aos benefícios produzidos pelo exercício regular. O treinamento físico parece ser uma estratégia interessante a ser estudada para a restauração do sistema antioxidante e de alterações comportamentais que ocorrem na PKU. / Phenylketonuria (PKU) is an inborn error of metabolism caused by deficiency of phenylalanine hydroxylase, resulting in accumulation of phenylalanine and its metabolites in blood and tissues. Hyperphenylalaninemia (HPA) causes serious damage in the brain probably due to increased oxidative stress and decreased availability of other large neutral amino acids (LNAA), among other mechanisms. Patients early diagnosed are also subject to these imbalances. The objective of this study was to evaluate: a) the effect of acute HPA model on the concentration of LNAA in plasma and total brain, b) the effect of regular exercise on parameters of oxidative stress in total brain, catecholamine content in suprarenal and behavioral aspects in a chronic HPA model. HPA was induced by subcutaneous administration of alpha-methylphenylalanine and phenylalanine, while SAL group received saline. For the acute model, rats were divided into groups Saline (SAL) and HPA (n = 3). Animals were killed 1 h after last injection, at the second day of treatment. For the chronic model, animals were divided into sedentary group (Sed) or exercise group (Exe), and subdivided into SAL (n=16-20) and HPA (n=16-20). Administration continued as long as 17 days. Exe groups performed two weeks of daily aerobic exercise lasting 20 min. At the 17th day, 1 h after injection, the animals performed the first exposure to open field task, and 24 h later, performed the second session. After that, animals were killed and the whole brain was homogenized to evaluate lipid peroxidation through the content of thiobarbituric acid reactive substances (TBA-RS), and activity of antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Suprarenal glands were collected for catecholamine content analysis. Acute HPA increased phenylalanine and decreased tyrosine in plasma and brain as well as decreased levels of other LNAA in the brain. Chronically, HPA increased TBA-RS and SOD activity, and reduced CAT and GPx activities in the brain and reduced catecholamine content into suprarenal. Regular exercise was able to prevent all the alterations found in HPA group, except for SOD activity. Regarding the behavioral data, HPA caused a decrease of habituation memory and regular exercise prevented this change. Exercise per se (ExeSAL group) produced no changes. HPA rats were more responsive to the benefits produced by regular exercise. Physical training appears to be an interesting strategy to be studied for the restoration of the antioxidant system and the behavioral changes that occur in PKU.

Introdução: A Hiperfenilalaninemia por deficiência de fenilalanina hidroxilase (HPAPAH) é um erro inato do metabolismo no qual ocorre aumento dos níveis séricos de fenilalanina (Phe). Estudos recentes, realizados em várias populações, demonstraram que pacientes com HPA-PAH podem apresentar redução das concentrações plasmáticas de Phe mediante a administração oral de tetrahidrobiopterina (BH4). Objetivo: Identificar em uma amostra de pacientes brasileiros com HPA-PAH aqueles que são responsivos à administração de BH4 por via oral. Métodos: Para um paciente ser incluído no estudo, era necessário ter diagnóstico de HPA-PAH e idade igual ou superior a 7 anos, estar em tratamento dietético e apresentar nível de Phe igual ou superior a 6 mg/dL em todas as medidas realizadas no ano anterior à inclusão no estudo. No dia anterior à sobrecarga de BH4 (Dia 1), os pacientes foram submetidos a três coletas de sangue para mensuração dos níveis de Phe. No Dia 2, os pacientes receberam dose única de 20mg/Kg de BH4. As coletas de sangue foram, então, realizadas nos pontos de hora: 0, 4 e 8h (Dia 2) e 24h (Dias 3) após a ingestão do medicamento. Os níveis de Phe foram determinados através da espectrometria de massa in tandem. Foram utilizados dois critérios para definir a presença de responsividade ao BH4: Critério 1: redução 30% de Phe após 8h da administração do medicamento; Critério 2: redução 30% de Phe após 24h da administração do medicamento. Resultados: Dezoito pacientes foram incluídos no estudo, com mediana de idade de 14 anos, sendo 66,7% do sexo masculino. Onze apresentavam a forma clássica da doença e três a forma atípica. Três (forma clássica: 1, forma atípica: 2) e cinco (forma clássica: 2, forma atípica: 2 e forma não-definida: 1) pacientes foram considerados responsivos ao BH4 conforme critérios 1 e 2, respectivamente. Os níveis de Phe plasmáticos do dia anterior ao teste de sobrecarga não demonstraram variação nos pontos de hora (p=0,523). Entretanto, quando comparamos os níveis de Phe nos pontos de hora do dia pré e pós BH4, encontrou-se variação significativa entre eles (p=0,006). A análise da associação genótipo-fenótipo, para os pacientes com dados disponíveis (n=6) mostrou que a mesma é multifatorial. Conclusão: Nossos achados estão de acordo com a literatura, e indicaram que um número considerável de pacientes brasileiros com HPA-PAH poderá ser beneficiado com a administração oral de BH4. / Introduction: Hyperphenylalaninemia by phenylalanine hydroxylase deficiency (HPAPAH) is an inborn error of metabolism in which increased serum levels of phenylalanine (Phe) occur. Recent studies on several populations showed that patients with HPA-PAH can have their serum levels reduced when receiving oral tetrahydrobiopterin (BH4). Objective: to identify in a sample of Brazilian HPA-PAH the patients who are responsive to the oral administration of BH4. Methods: the following inclusion criteria were used: diagnosis of HPA-PAH, age 7 years, on dietary treatment and Phe levels 6 mg/dL in all tests performed one year prior to the inclusion in this study. On the day before the BH4 challenge (Day 1) 3 blood samples were obtained to measure Phe levels. Blood samples were also obtained at time points 0, 4, 8 hours (Day 2) and 24 h (Day 3) after the intake of the medication. Phe levels were determined by tandem mass spectrometry. Criteria used to define responsiveness to BH4 were: Criterion 1: Phe reduction 30% 8 hours after BH4 administration; Criterion 2: Phe reduction 30% 24 hours after BH4 administration. Results: a total of 18 patients with a mean age of 14 years were included in this study; of those, 66.7% were male. Eleven presented the classical form of the disease and 3, the atypical form. Three patients (classical form: 1, atypical form: 2) and 5 (classical form: 2; atypical form: 2; undefined form: 1) were considered responsive to BH4 according to criteria 1 and 2, respectively. Phe serum levels on the Day 1 did not show any change on the established time point schedule (p=0.523). However, when comparing levels of Phe between Days 1 and 2, significant variation was found (p=0.006). The phenotype – genotype association analysis of patients with available data (n=6) showed that the association is multifactorial. Conclusion: In accordance with the literature, our findings show that many Brazilian patients with HPA-PAH can benefit from the oral administration of BH4.

The aim of this thesis is to identify innovation opportunities, which will serve to encourage individuals with inborn metabolic disorder phenylketunuria (also PKU) to comply with their strict dietary restrictions. The theoretical part of the thesis is devoted to the definition of basic concepts of innovation and techniques of Design thinking focusing on the Human-centered design approach. Futhermore the reader will find introduction into inborn metabolic disorder phenylketonuria. The practical part contains a plan of research, description of the current situation on the Czech market, outputs of research with experts, outputs of the workshop with individuals with PKU and the identification of innovation opportunities and recommendations.

The master's thesis deals with inherited metabolic disorder phenylketonuria from a marketing point of view. The theoretical basis of this thesis points out to differences between the marketing mix in the pharmaceutical industry and other industries. Analysis of marketing mix of Nutricia company in relation to patients with phenylketonuria is based on these facts. Secondary and primary data are used in this master's thesis. There were several research methods used to get the information, such comparison and telephone interviews. The work provides insights and recommendations in relation to the potential competitive advantages of the Nutricia company, which can help to maintain its position as market leader in the future. Attention is mostly paid to project such Home Deliveery and on-line communication.

The diploma thesis focuses on the National association of PKU and other inherited disorders. Within the theoretical part the non-profit sector is defined, the theoretical basis for marketing communication are determined and successful communication campaigns of non-profit organisations are introduced. The main goal of the diploma thesis is to suggest the communication strategy for the National association of PKU and other inherited disorders. The main goal of the diploma theses is supported by own research in the form of in-depth interviews and survey which were answered by PKU patients. Finally, the communication strategy proposal is created, which target is to raise awareness about PKU among the general public.

A fenilcetonúria (PKU) é uma doença metabólica causada pela deficiência da enzima fenilalanina hidroxilase, levando ao acúmulo de fenilalanina. As principais características clínicas dos pacientes com PKU não tratados são o comprometimento neuropsicológico e o retardo no desenvolvimento. O estresse oxidativo tem sido detectado em muitos erros inatos do metabolismo, incluindo PKU. A silibinina é um flavonoide proveniente da planta cardo de leite (Silybum marianum) que apresenta propriedades antioxidantes e que, após administração, é amplamente distribuída pelos tecidos. Neste trabalho, nós investigamos os efeitos da silibinina in vivo e in vitro contra o estresse oxidativo causado por elevados níveis de fenilalanina. Ratos machos e fêmeas, com 12 dias de vida no início dos experimentos, receberam injeções subcutâneas de α- metilfenilalanina e fenilalanina para realizar o modelo agudo de hiperfenilalaninemia, e o tratamento com silibinina consistiu em injeções intraperitoniais da substância na dose de 20 mg/kg. Os animais foram mortos no 14° dia de vida. Para realizar os experimentos in vitro, homogeneizados de córtex cerebral de ratos de 14 dias de vida foram incubados com fenilalanina e silibinina. In vitro e in vivo, a silibinina foi capaz de prevenir a inibição provocada pela fenilalanina nas atividades das enzimas catalase, glutationa peroxidase e glicose-6-fosfato desidrogenase. Não foram verificadas diferenças entre os grupos nas atividades da superóxido dismutase e da glutationa redutase. Além disso, a silibinina preveniu as alterações provocadas pela fenilalanina no conteúdo de carbonilas proteicas, nas substâncias reativas ao ácido tiobarbitúrico e na produção de espécies reativas. A silibinina preveniu o dano oxidativo induzido pela fenilalanina e pode ser uma potencial terapia complementar para o tratamento da PKU. / Phenylketonuria (PKU) is a metabolic disorder caused by a deficiency of phenylalanine hydroxylase, leading to accumulation of phenylalanine. The main clinical features of non-treated PKU patients are neuropsychological impairment and developmental retardation. Oxidative stress has been related to many inborn errors of metabolism including PKU. Silibinin is a flavonoid derived from the herb milk thistle (Silybum marianum) which presents antioxidant properties and is widely distributed into tissues after administration. In this study, we investigated the in vivo and in vitro effects of silibinin against oxidative stress caused by high levels of phenylalanine. Male and female rats, 12 days old at the beginning of experiments, received subcutaneous injections of α- methylphenylalanine and phenylalanine to produce hyperphenylalaninemia, and intraperitoneal injections of 20 mg/kg silibinin. The animals were killed on the 14th day of life. To perform in vitro experiments, cerebral cortex homogenates of 14 days old rats were incubated with phenylalanine and silibinin. In vivo and in vitro, silibinin was able to prevent the inhibition provoked by phenylalanine on the activities of catalase, glutathione peroxidase and glucose-6-phosphate dehydrogenase. No differences were found among the groups in the activities of superoxide dismutase and glutathione reductase. Moreover, silibinin prevented the alterations provoked by phenylalanine on protein carbonyl content, thiobarbituric acid-reactive substances and production of reactive species. Silibinin prevented oxidative damage induced by phenylalanine and may be a potential adjunctive therapy to PKU treatment.

Background Despite enormous advances in therapy, phenylketonuria (PKU) remains an incurable, inherited metabolic disease requiring life-long treatment with potential to negatively impact quality of life and psychological well-being. Therefore, the aim of this study was to screen early diagnosed and continuously treated children with PKU on psychological strengths and behavioral difficulties. Methods Evaluation of psychological strengths and behavioral difficulties in 49 patients with PKU (23f, 2-17 years) by Strengths and Difficulties Questionnaire (SDQ; self-report 11-17 years and parent-report 2-17 years). Comparison to age, sex and BMI-matched healthy controls (n = 98; 46f). Results In patients with PKU and healthy controls median SDQ Total Difficulties Score and median scores of subscales were within the normal range in parent- and self-report, irrespective of sex and age group (children 2-10 years, adolescents 11-17 years). No influence of long-term metabolic control in PKU on SDQ could be revealed. The 2- to 10-year-old boys with PKU showed significantly higher scores in Prosocial Behavior compared to their healthy peers (P = .032). Likewise, adolescent boys with PKU showed fewer Conduct Problems (parent-report, P = .006). Adolescent girls with PKU rated themselves more often as abnormal in the subscale Emotional Problems compared to their healthy peers (P = .041). This subscale was also responsible for a significantly different Total SDQ Difficulties Score between patients and their parents' report (P = .008). Discussion SDQ represents a suitable instrument within the care for patients with PKU. Specific aspects, however, require separate consideration and evaluation with respect to this chronic disease. Special attention should be paid on adolescent PKU girls who seem to be at risk to develop emotional problem.

Note:

No description available.

No description available.